MANNKIND CORP (MNKD)       4.57  -0.04 (-0.87%)

4.57  -0.04 (-0.87%)

US56400P7069 - Common Stock - After market: 4.57 0 (0%)


Fundamental Rating

3

Overall MNKD gets a fundamental rating of 3 out of 10. We evaluated MNKD against 635 industry peers in the Biotechnology industry. MNKD has a medium profitability rating, but doesn't score so well on its financial health evaluation. MNKD is quite expensive at the moment. It does show a decent growth rate.




Profitability

Profitability Rating

4

MNKD's Return On Assets of -33.19% is amongst the best of the industry. MNKD does better than the industry average Return On Assets of -44.83%.
MNKD has a Profit Margin of -127.93%. This is better than the industry average of -464.10%.

MNKD has negative profitability rations, so we won't be analyzing them here.
The Piotroski-F score of MNKD is 3.00. This is a low score and indicates issues in the health and profitability of MNKD.
VS Industry

ROA (-33.19%) VS Industry: 67% outperformed.

-3,944.82
115.38

Profit Margin (-127.93%) VS Industry: 69% outperformed.

-1,173,705.71
34,743.00

Valuation

Valuation Rating

0

The Price/Earnings Ratio is negative for MNKD. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MNKD. No positive earnings are expected for the next year.
VS Industry

Growth

Growth Rating

6

The Earnings Per Share is expected to grow by 22.16% on average over the next 5 years. This is a very strong growth
Based on estimates for the next 5 years, MNKD will show a very strong growth in Revenue. The Revenue will grow by 47.59% on average per year.
The Revenue growth is accelerating: in the next 5 years the growth will be better than in the last years.

Looking at the last year, MNKD shows a decrease in Revenue. The Revenue has decreased by -6.23% in the last year.
The earnings per share for MNKD have decreased strongly by -111.11% in the last year.
The Revenue for MNKD have been decreasing by -15.47% on average. This is quite bad

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPSN/A N/A -111.11% -60.01% 18.49% 42.15% 22.16%
Revenue-15.47% 39.32% -6.23% 12.9% 45.59% 52.09% 47.59%

Health

Health Rating

2

A Current Ratio of 3.66 indicates that MNKD has no problem at all paying its short term obligations.
A Quick Ratio of 3.36 indicates that MNKD has no problem at all paying its short term obligations.
When comparing the Current Ratio of MNKD to the average industry Current Ratio of 6.11, MNKD is less able to pay its short term obligations than its industry peers.
Compared to an average industry Quick Ratio of 6.02, MNKD is worse placed to pay its short term obligations than its industry peers.

The Debt to Equity ratio of MNKD is negative (-1.55). This means it has negative shareholder equity as the company's liabilities exceed its assets. This could be considered a sign of high risk.
MNKD has an Altman-Z score of -13.86. This is a bad value and indicates that MNKD is not financially healthy and even has some risk of bankruptcy.
When comparing the Altman-Z score of MNKD to the average industry Altman-Z score of -0.65, MNKD is less financially healthy than its industry peers. 89% of its industry peers have a better Altman-Z score.
MNKD has a quite weak Piotroski-F score of 3.00. This indicates issues in the health and profitability of MNKD.
VS Industry

Quick Ratio (3.36) VS Industry: 29% outperformed.

0.02
84.53

Current Ratio (3.66) VS Industry: 31% outperformed.

0.02
85.09

Altman-Z (-13.86) VS Industry: 11% outperformed.

-1,822.12
441.73

Dividend

Dividend Rating

0

MNKD does not give a dividend.

MNKD Daily chart

MANNKIND CORP4.57

NASDAQ:MNKD (12/6/2022, 7:00:01 PM)-0.04 (-0.87%)

After market: 4.57 0 (0%)

Chartmill FA Rating
GICS Sector Health Care
GICS IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry Biotechnology
Earnings (Last) 11-08 2022-11-08/bmo Earnings (Next) 02-22 2023-02-22
Ins Owners 2.62% Inst Owners 49.36%
Market Cap 1.20B Analysts 85
Valuation
PE N/A Fwd PE N/A
PEG (NY) N/A PEG (5Y) N/A
P/S 15.78 P/B N/A
EV/EBITDA -17.25
Dividend
Dividend Yield N/A Dividend Growth N/A
DP N/A Ex-Date N/A
Growth
EPS 1Y -111.11% EPS 3Y N/A
EPS 5Y N/A EPS growth Q2Q -200%
EPS Next Y -60.01% EPS Next 2Y 18.49%
EPS Next 3Y 42.15% EPS Next 5Y 22.16%
Revenue growth 1Y -6.23% Revenue growth 3Y 39.32%
Revenue growth 5Y -15.47% Revenue growth Q2Q 47.79%
Revenue Next Year 12.9% Revenue Next 2Y 45.59%
Revenue Next 3Y 52.09% Revenue Next 5Y 47.59%
Health
Current Ratio 3.66 Quick Ratio 3.36
Altman-Z -13.86 F-Score 3
Debt/Equity -1.55 WACC 9.09%
ROIC/WACC N/A
Profitability
ROA -33.19% ROE N/A
ROICexgc N/A ROIC N/A
PM -127.93% OM -111.69%
Asset Turnover 0.26

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA